GLP1R and COVID-19: In this nationwide cohort of patients with T2DM, the use of SGLT2i and of DPP-4i wasassociated with a higher risk of incident severe COVID-19, defined as hospitalization for ordeath from COVID-19, whereas GLP-1 RA use was numerically associated with an increased riskbut without reaching statistical significance.